Nutraceuticals target androgen receptor-splice variants (AR-SV) to manage castration resistant prostate cancer (CRPC)
Every year, prostate cancer is diagnosed in millions of men. The androgen receptor's (AR)
unchecked activation is crucial in causing the development and progression of prostate …
unchecked activation is crucial in causing the development and progression of prostate …
[HTML][HTML] Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer
The nuclear hormone family of receptors regulates gene expression. The androgen receptor
(AR), upon ligand binding and homodimerization, shuttles from the cytosol into the nucleus …
(AR), upon ligand binding and homodimerization, shuttles from the cytosol into the nucleus …
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer
L Poluben, M Nouri, J Liang, S Chen, A Varkaris… - Cell Reports, 2025 - cell.com
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in
castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear …
castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear …
Androgen receptor inhibitors in treating prostate cancer
RN Cole, Q Fang, K Matsuoka… - Asian Journal of …, 2024 - journals.lww.com
Androgens play an important role in prostate cancer development and progression.
Androgen action is mediated through the androgen receptor (AR), a ligand-dependent DNA …
Androgen action is mediated through the androgen receptor (AR), a ligand-dependent DNA …
CYR61 promotes metastasis of prostate cancer cells through the p-AKT and AR signaling pathways
Background Previous studies have shown that the cysteine-rich angiogenic inducer 61
(CYR61) contributes to prostate cancer (PCa) cell growth and survival, but its role in PCa …
(CYR61) contributes to prostate cancer (PCa) cell growth and survival, but its role in PCa …
[PDF][PDF] Targeting Androgen Receptor Variants in Castration-Resistant Prostate Cancer (CRPC)
I Omeye Francis - rijournals.com
Castration-resistant prostate cancer (CRPC) remains a lethal stage of prostate cancer,
characterized by resistance to androgen deprivation therapy (ADT) and poor clinical …
characterized by resistance to androgen deprivation therapy (ADT) and poor clinical …